Harshad Kulkarni

Chief Medical Advisor Bamf Health

Seminars

Wednesday 12th November 2025
Target Absorbed Dose, Not Activity? Personalizing Radiopharmaceutical Therapy: A Challenge to Current Practice
2:30 pm
  • Reframing the target: Dose ≠ Activity. Define terms, show where fixed-activity regimens fall short, and summarize evidence that absorbed dose correlates better with efficacy and toxicity than administered activity
  • Personalization levers: Intervals, cycle count, and per-cycle activity. Walk through practical, response-adaptive scheduling using early imaging and dosimetry to hit tumor dose goals while respecting organ-at-risk limits
  • What industry should test next: Pragmatic designs and infrastructure. Dose-targeted arms vs activity presets, feasible dosimetry workflows, safety stopping rules, manufacturing, regulatory and operational implications, and the key unknowns to resolve
Wednesday 12th November 2025
Bridging Clinical & Industry Priorities for TRP Trial Success
11:30 am
  •  Identifying the right clinical partners: who to approach
  • Navigating variability across institutions in TRP trial experience and infrastructure
  • Aligning timelines, expectations, and communication between sponsors and sites
Harshad Kulkarni, Chief Medical Advisor, Bamf Health